Role of vasoactive factors in the pathogenesis of early changes in diabetic retinopathy

Diabetes/Metabolism Research and Reviews

Volumn 16, Issue 6, 2000, Pages 393-407

  Chakrabarti, Subrata ^a   Cukiernik, Mark ^a   Hileeto, Denise ^a   Evans, Terry ^a   Chen, Shali ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Diabetic retinopathy; Endothelins; Nitric oxide; Non enzymatic glycation; PKC; Polyol pathway; Vascular endothelial growth factor

Indexed keywords

ENDOTHELIN; NITRIC OXIDE; POLYOL; PROTEIN KINASE C; VASCULOTROPIN; VASOACTIVE AGENT;

DIABETIC RETINOPATHY; ENZYME ACTIVATION; GLYCATION; HUMAN; HYPERGLYCEMIA; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; RETINA; REVIEW;

ANIMALS; DIABETIC RETINOPATHY; ENDOTHELIAL GROWTH FACTORS; ENDOTHELINS; GROWTH SUBSTANCES; HUMANS; LYMPHOKINES; NITRIC OXIDE; RETINA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034507970     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/1520-7560(0000)9999:9999<::AID-DMRR157>3.0.CO;2-G     Document Type: Review

References (199)

1. The effect of intensive treatment of diabetes on the development of long-term complications in insulin-dependent diabetes mellitus
2. Perspectives in Diabetes. Hyperglycemic pseudohypoxia and diabetic complications
3. Recent progress in advanced glycation end products and diabetic complications
4. The sorbitol-osmotic and sorbitol-redox hypotheses
5. The cellular and molecular mechanisms of diabetic complications
6. Protein kinase C activation and the development of diabetic complications
7. Retinal vascular patterns VI. Mural cells of the retinal capillaries
8. Accelerated death of retinal microvascular pericytes in human and experimental diabetic retinopathy
9. Endothelium: The main actor in the remodelling of the retinal microvasculature in diabetes
10. Comparison of retinal lesions in alloxan-diabetic rats and galactose-fed rats
11. Anionic sites in diabetic basement membranes and their possible role in diffusion barrier abnormalities
12. Coagulation activation in diabetes mellitus: The role of hyperglycemia and therapeutic prospects
13. Decreased antithrombin III activity in diabetes may be due to non-enzymatic glycosylation. A preliminary report
14. Stereological estimation of Weibel-Palade bodies in the retinal vasculature of normal and diabetic dogs
15. In vivo demonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats
16. Protein kinase C (PKC) activation is a causal factor for the alteration of retinal blood flow in diabetes of short duration
17. 3H-desmethylimiprimine) microspheres
18. Retinal blood flow by hydrogen clearance polarography in the streptozotocininduced diabetic rat
19. Glucose-induced metabolic imbalances in the pathogenesis of diabetic vascular disease
20. Inhibition of sorbitol dehydrogenase. Effects on vascular and neural dysfunction in streptozocin-induced diabetic rats
21. Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation
22. Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors
23. Glucose-induced increases in ocular blood flow are prevented by aminoguanidine and LNMMA, inhibitors of nitric oxide synthase
24. Endoneurial blood flow changes in diabetic rats
25. Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway
26. Normalization of retinal blood flow in diabetic rats with primary intervention using insulin pumps
27. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor
28. Diabetes induced dysfunction in the retina: Role of endothelins
29. Endothelins, their receptors, and retinal vascular dysfunction in galactose-fed rats
30. Sorbinil prevents diabetes induced vascular permeability but does not alter collagen cross-linking
31. Increased vascular permeability in spontaneously diabetic BB/W rats and in rats with mild versus severe streptozotocin induced diabetes: Prevention by aldose reductase inhibition and castration
32. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor
33. Early morphological alteration of the pigment epithelium in the streptozotocin induced diabetes: Increased surface area of basal cell membrane
34. Pathologic studies of the blood retinal barrier in the spontaneously diabetic BB-rat
35. Anionic sites in diabetic basement membranes and their possible role in diffusion barrier abnormalities
36. Effect of propionyl-L-carnitine on oscillatory potentials in electroretinogram in streptozotocin-diabetic rats
37. Effect of an aldose reductase inhibitor on abnormalities of electroretinogram and vascular factors in diabetic rats
38. Development of electroretinographic alterations in streptozotocin-induced diabetes in rats
39. The development of electroretinogram abnormalities and possible roles of polyol pathway activity in diabetic hyperglycemia and galactosemia
40. Treatment with an aldose reductase inhibitor or with myo-inositol arrests deterioration of electroretinogram of diabetic rats
41. Optic neuropathy in the diabetic BB rat
42. Impaired visual evoked potential and primary axonopathy of the optic nerve in the diabetic BB/W rat
43. The preventive effect of aldose reductase inhibition on diabetic optic neuropathy in the BB/W rat
44. Retinopathy in animal models of diabetes
45. Downregulation of the human taurine transporter by glucose in cultured retinal pigment epithelial cells
46. Diacylglycerol accumulation and microvascular abnormalities induced by elevated glucose levels
47. Endothelial dysfunction in diabetic vascular disease
48. Glucose dependence of glycolysis, hexode monophosphate shunt activity, energy status, and the polyol pathway in retinas isolated from normal (nondiabetic) rats
49. 1adrenoceptor antagonist and antioxidant therapy on diabetes-induced changes in retinal NAD(P)-Redox status: Evidence against «Pseudohypoxia?» [C]
50. Free radicals, nitric oxide and diabetic complications
51. The autoxidation of glyceraldehyde and other simple monosaccharides
52. Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing
53. Hydrogen peroxide production during experimental protein glycation
54. The oxidation of oxyhaemoglobin by glyceraldehyde and other simple monosaccharides
55. Effect of insulin on impaired antioxidant activities in aortic endothelial cells from diabetic rabbits
56. Abnormalities of retinal metabolism in diabetes or galactosemia: ATPases and glutathione
57. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. IV. Antioxidant defense system
58. Glycation and inactivation of human Cu-Zn-superoxide dismutase. Identification of the in vitro glycated site
59. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
60. Regulation of protein kinase C
61. PKC μ is a novel, atypical member of the protein kinase C family
62. Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1
63. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation
64. Characterization of the mechanism for the chronic activation of DAG-PKC pathway in diabetes and hypergalactosemia
65. Abnormalities of retinal metabolism in diabetes or experimental galactosemía. III. Effects of antioxidants
66. Increased endothelial albumin permeability mediated by protein kinase C activation
67. Enhanced expression of inducible nitric oxide synthase in murine macrophages and glomerular mesangial cells by elevated glucose levels: Possible mediation via Protein kinase C
68. The role of growth factors in the pathogenesis of diabetic vascular complications
69. Significance of fructose-induced protein oxidation and formation of advanced glycation end product
70. Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction
71. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGEinfused rats
72. Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells
73. The role of oxidative stress and NF-kappaB activation in late diabetic complications
74. Endothelial receptor mediated binding of glucose modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties
75. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor
76. Altered cellular interaction between endothelial cells and non-enzymatically glucosylated laminin/type IV collagen
77. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes
78. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells
79. An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes
80. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans
81. Endothelins: Molecular biology, biochemistry, pharmacology, physiology and pathophysiology
82. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
83. Regulation of growth factor mRNA levels in the eyes of diabetic rats
84. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes
85. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
86. Endothelin-1 and endothelin-3 like immunoreactivity in the eyes of diabetic and non-diabetic BB/ W rats
87. Ocular effects of endothelins, abundant peptides in the eye
88. Endothelins
89. Endothelin-1 and endothelin receptor antagonists in cardiovascular remodelling
90. Cellular mechanisms of thrombin on endothelin-1 biosynthesis and release in bovine endothelial Cells
91. Transforming growth factor beta stimulates the expression of endothelin mRNA from vascular endothelial cells
92. Transcriptional regulation of the endothelin gene by TNF alpha
93. Pathophysiology of endothelin in the cardiovascular system
94. Cellular mechanism of natriuretic [C] peptides-induced inhibition of endothelin-1 biosynthesis in rat endothelial cells
95. Heparin has an inhibitory effect on endothelin-1 synthesis and release by endothelial cells
96. Molecular characterization of endothelin receptors
97. Clozel M Endothelin antagonism with bosentan: A review of potential applications
98. Endothelin-1 modulates vascular smooth muscle structure and vasomotion: Implications in cardiovascular pathology
99. B receptors mediate contraction to endothelin-1 in human blood vessels
100. Differential regulation of fos and jun gene expression and AP-1 cis element activity by endothelin isopeptides: Possible implications for mitogenic signalling by endothelin
101. Endothelin: Emerging role in diabetic vascular complications
102. Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine aortic endothelial cells
103. Regulation of endothelin-1 (ET-1) expression in the endothelial cells in normo- and hyperglycemic conditions
104. Insulin stimulates production and secretion of endothelin from bovine endothelial cells
105. Immunoreactive endothelin distribution in ocular tissue
106. B gene expression in chronic diabetes
107. Regulation of retinal hemodynamics in diabetic rats by increased expression and action of endothelin-1
108. Regulation of mRNA expression for ECM by cultured rat mesangial cells
109. Effect of a specific endothelin-A receptor antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli
110. Alteration of growth-related protooncogene expression in diabetic glomeruli by a specific endothelin receptor A antagonist
111. Hyperhexosemia induced extracellular matrix protein gene expression and basement membrane thickening in the retinal microvasculature are mediated via augmented endothelin production
112. Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose fed rats
113. Contribution of protein kinase C to ET-1-induced proleration in human myometrial cells
114. Endothelinstimulated phosphoinositide turnover and protein kinase C translocation in rat synaptosomes
115. A matter of life and breath
116. Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion
117. An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia
118. Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes
119. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas
120. Upregulation of the vascular endothelial growth factor/ vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat
121. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
122. Vascular permeability factor, an endothelial cell mitogen related to PDGF
123. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing
124. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor
125. Neovasculature induced by vascular endothelial growth factor is fenestrated
126. Vascular endothelial growth factor induces endothelial fenestrations in vitro
127. Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation
128. Vascular endothelial growth factor is a secreted angiogenic mitogen
129. Vascular endothelial growth factor: A new member of the plateletderived growth factor gene family
130. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA
131. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix
132. Differential expression of vascular endothelial growth factor (vascular permeability factor) forms in rat tissues
133. The human gene for vascular endothelial growth factor Multiple protein forms are encoded through alternative exon splicing
134. The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF
135. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells
136. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
137. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
138. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation
139. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I
140. Cell release of bioactive fibroblast growth factor 2 by exon 6-encoded sequence of vascular endothelial growth factor
141. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo
142. Inhibition of vascular endothelial growth factor prevents retinal ischemiaassociated iris neovascularization in a nonhuman primate
143. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate
144. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
145. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
146. Failure of bloodisland formation and vasculogenesis in Flk-1-deficient mice
147. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
148. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy
149. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases
150. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
151. VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF Receptor 2 (KDR)
152. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells
153. Suppression of hypoxia-associated vascular endothelial growth factor gene expression by nitric oxide via cGMP
154. Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression
155. Nitric oxide synthases: Roles, tolls and controls
156. Free radicals, nitric oxide and diabetic complications
157. The high output nitric oxide pathway: Role and regulation
158. Differential regulation of nitric oxide synthase-II mRNA by growth factors in rat, bovine, and human retinal pigmented epithelial cells
159. Interaction between endothelin and endothelial derived relaxing factors
160. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C
161. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products
162. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence
163. Impaired endothelium-dependent and independent vasodilaton in patients with Type 2 (non-insulin-dependent) diabetes mellitus
164. Free radicals in diabetic endothelial cell dysfunction
165. Bioassay of endothelium-derived relaxing factor in diabetic rat aorta
166. Impaired nitric oxidedependent cyclic guanosine monophosphate generation in glomeruli from diabetic rats: Evidence for protein kinase C-mediated suppression of the cholinergic response
167. Exposure to elevated d-glucose concentrations modulates vascular endothelial cell vasodilatory response
168. Regulation of spontaneous EDRF release in diabetic rat aorta by oxygen free radicals
169. Dysfunction of vascular endothelium in diabetes mellitus
170. The role of growth factors in the development of diabetic retinopathy
171. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro
172. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels
173. Basic FGF-induced down-regulation of IGF-1 mRNA in cultured rat Muller cells
174. Essential role of growth hormone in ischemia-induced retinal neovascularisation
175. Receptors and growth-promoting effects of insulin and insulin-like growth factors on cells from bovine retinal capillaries and aorta
176. Antiapoptotic signaling by the insulin-like growth factor-1 receptor, phosphatidylinositol 3-kinase and Akt
177. Down-regulation of protein kinase C inhibits insulin-like growth factor 1-induced vascular smooth muscle cell proliferation, migration and gene expression
178. Cotherapy with recombinant human insulinlike growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I in IDDM study group
179. Regulation of bFGF expression and ANG II secretion in cardiac myocytes and microvascular endothelial cells
180. Angiotension II and endothelin-1 increase fibroblast growth factor-2 mRNA expression in vascular smooth muscle cells
181. Insulin and IGF-I attenuate the coronary vasoconstrictor effects of endothelin-1 but not of sarafotoxin 6c
182. Dual effects of insulin-like growth factor-I on the constitutive and inducible nitric oxide (NO) synthasedependent formation of NO vascular cells
183. Prevention of vascular and neural dysfunction in diabetic rats by C-peptide
184. Insulin-induced vascular endothelial growth factor expression in retina
185. The effects of endothelin and bFGF on proliferation of MC and synergetic effect of insulin
186. Eicosanoids, prostaglandins, thromboxanes, leukotrienes, and other derivatives of carbon-2 unsaturated fatty acids
187. Role of prostaglandin H2 as an endothelium-derived contracting factor in diabetic state
188. Decreased vascular prostacyclin in experimental diabetes
189. 2-isoprostanes) are formed in situ on phospholipids
190. 2-isoprostane receptors on rat vascular smooth muscle cells
191. 2α in vascular smooth muscle cells (VSMC) by elevated glucose and growth factors
192. Role of specific isoforms of protein kinase C in angiotensin II and lipoxygenase action in rat adrenal glomerulosa cells
193. Role of the lipoxygenase pathway in angiotensin II-induced vascular smooth muscle cell hypertrophy
194. Endothelin 1 stimulates Na +, K(+)-ATPase and Na (+)-K(+)-C1-cotransport through ETA receptors and protein kinase C-dependent pathway in cerebral capillary endothelium
195. Endothelial relaxation is disturbed by oxidative stress in the diabetic rat heart: Influence of tocopherol as antioxidant
196. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth
197. Vascular endothelial growth factor-induced endothelial cell migration and proliferation depend on a nitric oxide-mediated decrease in protein kinase C delta activity
198. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy
199. The effect of the aldose reductase inhibitor, ponalrestat, on the progression of diabetic retinopathy